PERCEPTIVE CAPITAL SOLUTIONS
PCSCNASDAQ🏆 #3990 by market capUS Equity
$11.95▲ $0.00 (+0.00%)
LiveTrack PCSC
Get earnings, price moves & breaking news on Telegram
24h▲ 0.0%
7d▼ 0.6%
14d▼ 0.6%
30d▼ 0.6%
ytd▼ 9.1%
1y▲ 13.3%
🏦Market Cap
$124M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
100.0%
High
💵FCF Margin
-109.8%
Thin
⚖️P/S Ratio
150.6x
Expensive
Otter Score
56
Weak
Trading Snapshot
- Day Range
- $11.82 – $12.05
- 52-Week Range
- $9.95 – $14.47
- Volume
- $3.49B
- Avg Volume
- $3.56B
- Shares Outstanding
- 10.4M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $826,382
- Last Q Revenue
- $826,382
- P/E Ratio
- -168.5
- P/S Ratio
- 150.6x
- EPS (TTM)
- $-0.09
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +32.6%
Why Investors Own PCSC
- ✓High-growth profile — revenue up +4.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PERCEPTIVE CAPITAL SOLUTIONS
PCSCFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▲ +503.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$865K▲ +21.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.1M▲ +32.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$865K▼ −$265K YoY
StockOtter · stockotter.spaceAbout PERCEPTIVE CAPITAL SOLUTIONS
Currently, Perceptive Capital Solutions Corp possesses no significant active operations. Its principal objective is to execute a strategic business combination—such as a merger, share swap, asset procurement, equity acquisition, or corporate restructuring—with one or more enterprises or entities engaged in the life sciences and medical technology sectors. These prospective partners are sought exclusively within North America or Europe. The company was established in 2024, with its corporate base located in New York, New York.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100
Analyst Price Target
ⓘAverage Target
$12.70
▲ +6.2% Upside
High Target$15.71
Low Target$11.34
Based on 15 analysts
